← Ashland Global overview

Ashland Global vs Shin-Etsu Chemical Co.: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ashland Global Holdings Inc (ASH)

Q3 2026
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

August 2026
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Latest
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Shin-Etsu Chemical Co., Ltd. (4063.JP)

Q3 2026
▲2▼2

Shin-Etsu: AI demand and photoresist price hikes offset profit miss and China trade hit

  • NVIDIA deepens ties with Japanese suppliers, boosting wafer demand NVIDIA's CEO met with Shin-Etsu and other Japanese suppliers, signaling that AI expansion will keep driving demand for Shin-Etsu's silicon wafers. More AI chips mean more wafer sales, which supports future revenue and profits.

    This is a new demand signal that directly supports Shin-Etsu's core semiconductor materials business.

  • Full-year profit forecast misses market expectations, shares drop 8% Shin-Etsu projected net profit of 525 billion yen, below the 566.8 billion yen analysts expected. The weak outlook, partly from poor vinyl chloride conditions, caused the stock to fall over 8% as investors lowered their expectations.

    This is a new negative event that directly hit the stock price and reflects a real earnings shortfall.

  • Photoresist price hikes of up to 38% lift margins Shin-Etsu and peers are raising photoresist prices by 15% overall from October 1, with high-end grades up to 38% for spot orders. Higher prices should boost Shin-Etsu's revenue and profit margins in this key product line.

    This is a new pricing action that directly improves profitability for a major Shin-Etsu product.

  • China imposes up to 99.2% anti-dumping deposits on Shin-Etsu's dichlorosilane China will require deposits of up to 99.2% on imports of Shin-Etsu's dichlorosilane, a semiconductor material, starting September 8. This trade measure, seen as pressure on Japan, could hurt Shin-Etsu's sales to China and add uncertainty.

    This is a new regulatory/trade action that directly threatens Shin-Etsu's exports and adds a real counterweight.

August 2026
▲2▼2

Shin-Etsu: AI demand and photoresist price hikes offset profit miss and China trade hit

  • NVIDIA deepens ties with Japanese suppliers, boosting wafer demand NVIDIA's CEO met with Shin-Etsu and other Japanese suppliers, signaling that AI expansion will keep driving demand for Shin-Etsu's silicon wafers. More AI chips mean more wafer sales, which supports future revenue and profits.

    This is a new demand signal that directly supports Shin-Etsu's core semiconductor materials business.

  • Full-year profit forecast misses market expectations, shares drop 8% Shin-Etsu projected net profit of 525 billion yen, below the 566.8 billion yen analysts expected. The weak outlook, partly from poor vinyl chloride conditions, caused the stock to fall over 8% as investors lowered their expectations.

    This is a new negative event that directly hit the stock price and reflects a real earnings shortfall.

  • Photoresist price hikes of up to 38% lift margins Shin-Etsu and peers are raising photoresist prices by 15% overall from October 1, with high-end grades up to 38% for spot orders. Higher prices should boost Shin-Etsu's revenue and profit margins in this key product line.

    This is a new pricing action that directly improves profitability for a major Shin-Etsu product.

  • China imposes up to 99.2% anti-dumping deposits on Shin-Etsu's dichlorosilane China will require deposits of up to 99.2% on imports of Shin-Etsu's dichlorosilane, a semiconductor material, starting September 8. This trade measure, seen as pressure on Japan, could hurt Shin-Etsu's sales to China and add uncertainty.

    This is a new regulatory/trade action that directly threatens Shin-Etsu's exports and adds a real counterweight.

Latest
▲2▼2

Shin-Etsu: AI demand and photoresist price hikes offset profit miss and China trade hit

  • NVIDIA deepens ties with Japanese suppliers, boosting wafer demand NVIDIA's CEO met with Shin-Etsu and other Japanese suppliers, signaling that AI expansion will keep driving demand for Shin-Etsu's silicon wafers. More AI chips mean more wafer sales, which supports future revenue and profits.

    This is a new demand signal that directly supports Shin-Etsu's core semiconductor materials business.

  • Full-year profit forecast misses market expectations, shares drop 8% Shin-Etsu projected net profit of 525 billion yen, below the 566.8 billion yen analysts expected. The weak outlook, partly from poor vinyl chloride conditions, caused the stock to fall over 8% as investors lowered their expectations.

    This is a new negative event that directly hit the stock price and reflects a real earnings shortfall.

  • Photoresist price hikes of up to 38% lift margins Shin-Etsu and peers are raising photoresist prices by 15% overall from October 1, with high-end grades up to 38% for spot orders. Higher prices should boost Shin-Etsu's revenue and profit margins in this key product line.

    This is a new pricing action that directly improves profitability for a major Shin-Etsu product.

  • China imposes up to 99.2% anti-dumping deposits on Shin-Etsu's dichlorosilane China will require deposits of up to 99.2% on imports of Shin-Etsu's dichlorosilane, a semiconductor material, starting September 8. This trade measure, seen as pressure on Japan, could hurt Shin-Etsu's sales to China and add uncertainty.

    This is a new regulatory/trade action that directly threatens Shin-Etsu's exports and adds a real counterweight.